Literature DB >> 22316089

Reduction in duration of hypoglycemia by automatic suspension of insulin delivery: the in-clinic ASPIRE study.

Satish Garg1, Ronald L Brazg, Timothy S Bailey, Bruce A Buckingham, Robert H Slover, David C Klonoff, John Shin, John B Welsh, Francine R Kaufman.   

Abstract

BACKGROUND: The efficacy of automatic suspension of insulin delivery in induced hypoglycemia among subjects with type 1 diabetes was evaluated. SUBJECTS AND METHODS: In this randomized crossover study, subjects used a sensor-augmented insulin pump system with a low glucose suspend (LGS) feature that automatically stops insulin delivery for 2 h following a sensor glucose (SG) value ≤70 mg/dL. Subjects fasted overnight and exercised until their plasma glucose (measured with the YSI 2300 STAT Plus™ glucose and lactate analyzer [YSI Life Sciences, Yellow Springs, OH]) value reached ≤85 mg/dL on different occasions separated by washout periods lasting 3-10 days. Exercise sessions were done with the LGS feature turned on (LGS-On) or with continued insulin delivery regardless of SG value (LGS-Off). The order of LGS-On and LGS-Off sessions was randomly assigned. YSI glucose data were used to compare the duration and severity of hypoglycemia from successful LGS-On and LGS-Off sessions and to estimate the risk of rebound hyperglycemia after pump suspension.
RESULTS: Fifty subjects attempted 134 sessions, 98 of which were successful. The mean±SD hypoglycemia duration was less during LGS-On than during LGS-Off sessions (138.5±76.68 vs. 170.7±75.91 min, P=0.006). During LGS-On compared with LGS-Off sessions, mean nadir YSI glucose was higher (59.5±5.72 vs. 57.6±5.69 mg/dL, P=0.015), as was mean end-observation YSI glucose (91.4±41.84 vs. 66.2±13.48 mg/dL, P<0.001). Most (53.2%) end-observation YSI glucose values in LGS-On sessions were in the 70-180 mg/dL range, and none was >250 mg/dL.
CONCLUSIONS: Automatic suspension of insulin delivery significantly reduced the duration and severity of induced hypoglycemia without causing rebound hyperglycemia.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22316089     DOI: 10.1089/dia.2011.0292

Source DB:  PubMed          Journal:  Diabetes Technol Ther        ISSN: 1520-9156            Impact factor:   6.118


  42 in total

Review 1.  Sensor-Augmented Insulin Pumps and Hypoglycemia Prevention in Type 1 Diabetes.

Authors:  Isabelle Steineck; Ajenthen Ranjan; Kirsten Nørgaard; Signe Schmidt
Journal:  J Diabetes Sci Technol       Date:  2016-10-06

2.  The Future of Glucose Monitoring.

Authors:  Satish K Garg
Journal:  Diabetes Technol Ther       Date:  2016-02       Impact factor: 6.118

3.  6(th) Annual Symposium on Self-Monitoring of Blood Glucose (SMBG) applications and beyond, April 25-27, 2013, Riga, Latvia.

Authors:  Aus Alzaid; Christof Schlaeger; Rolf Hinzmann
Journal:  Diabetes Technol Ther       Date:  2013-09-28       Impact factor: 6.118

4.  Continuous Glucose Monitoring Adherence: Lessons From a Clinical Trial to Predict Outpatient Behavior.

Authors:  Martin de Bock; Matthew Cooper; Adam Retterath; Jennifer Nicholas; Trang Ly; Timothy Jones; Elizabeth Davis
Journal:  J Diabetes Sci Technol       Date:  2016-05-03

Review 5.  The artificial pancreas: is it important to understand how the β cell controls blood glucose?

Authors:  Garry M Steil; Gerold M Grodsky
Journal:  J Diabetes Sci Technol       Date:  2013-09-01

6.  Factors affecting the success of glucagon delivered during an automated closed-loop system in type 1 diabetes.

Authors:  P A Bakhtiani; J El Youssef; A K Duell; D L Branigan; P G Jacobs; M R Lasarev; J R Castle; W K Ward
Journal:  J Diabetes Complications       Date:  2014-09-16       Impact factor: 2.852

7.  5(th) Annual Symposium on Self-Monitoring of Blood Glucose (SMBG) applications and beyond, May 3-5, 2012, Dublin, Ireland.

Authors:  Hilary Hoey; Anita Mlinac; Cam-Tuan Tran; Christof Schlaeger
Journal:  Diabetes Technol Ther       Date:  2012-12       Impact factor: 6.118

8.  Routine sensor-augmented pump therapy in type 1 diabetes: the INTERPRET study.

Authors:  Kirsten Nørgaard; Andrea Scaramuzza; Natasa Bratina; Nebojsa M Lalić; Przemyslaw Jarosz-Chobot; Győző Kocsis; Edita Jasinskiene; Christophe De Block; Odile Carrette; Javier Castañeda; Ohad Cohen
Journal:  Diabetes Technol Ther       Date:  2013-02-25       Impact factor: 6.118

Review 9.  Recreational diving in persons with type 1 and type 2 diabetes: Advancing capabilities and recommendations.

Authors:  Johan H Jendle; Peter Adolfsson; Neal W Pollock
Journal:  Diving Hyperb Med       Date:  2020-06-30       Impact factor: 0.887

Review 10.  Technology to optimize pediatric diabetes management and outcomes.

Authors:  Jessica T Markowitz; Kara R Harrington; Lori M B Laffel
Journal:  Curr Diab Rep       Date:  2013-12       Impact factor: 4.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.